Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The company said it is keeping an eye on TNF-like ligand 1A (TL1A) therapies to be used in combination with Skyrizi which it hopes could become the new standard of care. AbbVie also spoke about ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

US FDA approves Evolus' two new anti-wrinkle gels February 13, 2025 AbbVie forecast 2025 profit ... of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down ...

Bristol Myers forecasts steeper drop in 2025 revenue ... Healthcare dealmakers eye M&A resurgence in second Trump term January 13, 2025 Abbvie said on Friday it would record a charge of about ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

A new prescription eye drop called Vuity is offering a fresh solution for people struggling with presbyopia, a common ...

AbbVie is known for its work in several key therapeutic areas including immunology, oncology, neuroscience, and eye care, as well as products in the Allergan (NYSE:AGN) Aesthetics portfolio.

AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company commercializes ...

AbbVie will not be pursued any further by the US government over allegations that it used 'sham' litigation to keep competition to its AndroGel testosterone replacement product off the market.